WO2004106491A3 - Therapies du vih-1 basees sur l'engiogenine - Google Patents

Therapies du vih-1 basees sur l'engiogenine Download PDF

Info

Publication number
WO2004106491A3
WO2004106491A3 PCT/US2004/015781 US2004015781W WO2004106491A3 WO 2004106491 A3 WO2004106491 A3 WO 2004106491A3 US 2004015781 W US2004015781 W US 2004015781W WO 2004106491 A3 WO2004106491 A3 WO 2004106491A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
replication
angiogenin
viruses
therapies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/015781
Other languages
English (en)
Other versions
WO2004106491A8 (fr
WO2004106491A2 (fr
Inventor
Gene M Shearer
Maria T Rugeles
Susanna M Ryback
Joost J Oppenheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2004106491A2 publication Critical patent/WO2004106491A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004106491A3 publication Critical patent/WO2004106491A3/fr
Publication of WO2004106491A8 publication Critical patent/WO2004106491A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de traitement de virus hautement mutants et de virus établissant des infections chroniques ou latentes chez un individu. En particulier, il est montré que l'engiogénine constitue un inhibiteur puissant de la réplication virale telle que pour le VIH-1. Ceci présente plusieurs avantages par rapport à d'autres ribonucléases connues lesquelles sont utilisées pour inhiber la réplication du VIH-1 étant donné que l'engiogénine inhibe la réplication du VIH-1 dans des cultures primaires de lymphocytes T activés et des lignées cellulaires infectées chroniquement. L'inhibition de la réplication du VIH-1 dans des lymphocytes T activés primaires augmenterait le risque de développement du VIH vers d'autres cellules sensibles.
PCT/US2004/015781 2003-05-22 2004-05-19 Therapies du vih-1 basees sur l'engiogenine Ceased WO2004106491A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47296503P 2003-05-22 2003-05-22
US60/472,965 2003-05-22

Publications (3)

Publication Number Publication Date
WO2004106491A2 WO2004106491A2 (fr) 2004-12-09
WO2004106491A3 true WO2004106491A3 (fr) 2006-08-24
WO2004106491A8 WO2004106491A8 (fr) 2006-10-19

Family

ID=33490546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015781 Ceased WO2004106491A2 (fr) 2003-05-22 2004-05-19 Therapies du vih-1 basees sur l'engiogenine

Country Status (1)

Country Link
WO (1) WO2004106491A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2295969C1 (ru) * 2005-08-18 2007-03-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ стимуляции остеогенеза при переломах трубчатых костей
CA2702645C (fr) * 2006-11-10 2018-01-02 Agriculture Victoria Services Pty Ltd Procede de preparation de l'angiogenine
CA2723987C (fr) 2008-05-14 2019-06-11 Agriculture Victoria Services Pty Ltd Utilisation de l'angiogenine ou d'agonistes de l'angiogenine pour traiter des maladies et des troubles
RU2010150934A (ru) * 2008-05-14 2012-06-20 Эгрикалчер Виктория Сервисиз Пти Лтд (Au) Пероральный препарат
AU2013204721B2 (en) * 2008-05-14 2016-08-18 Agriculture Victoria Services Pty Ltd Methods for treating cachexia
RU2429002C1 (ru) * 2010-09-13 2011-09-20 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ стимуляции репаративного остеогенеза
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
US5171845A (en) * 1987-11-19 1992-12-15 Genevieve Spik Protein homologue of human angiogenin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171845A (en) * 1987-11-19 1992-12-15 Genevieve Spik Protein homologue of human angiogenin
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NG T.B. ET AL: "Inhibition of human immunodeficiency virus type 1 reverse transcriptase, protease and integrase by bovine milk proteins", LIFE SCIENCES, vol. 69, no. 19, 28 September 2001 (2001-09-28), pages 2217 - 2223, XP002995395 *
WANG H. ET AL: "First demonstration of an inhibitory activity of milk proteins against human immunodeficiency virus-1 reverse transcriptase and the effect of succinylation", LIFE SCIENCES, vol. 67, no. 22, 20 October 2000 (2000-10-20), pages 2745 - 2752, XP002995396 *

Also Published As

Publication number Publication date
WO2004106491A8 (fr) 2006-10-19
WO2004106491A2 (fr) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2005024422A3 (fr) Procedes permettant d'identifier des inhibiteurs
WO2005077050A3 (fr) Inhibiteurs de l'integrase du vih
Klockow et al. The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection
TW200630093A (en) Dose forms
WO2008045238A3 (fr) Peptides antiviraux hélicoïdaux courts thérapeutiques stabilisés
EA200700243A1 (ru) Способы лечения гепатита с
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
WO2006072624A3 (fr) Compositions et procedes de traitement d'infections virales
WO2003082200A3 (fr) Virus herpes simplex oncolytique puissant pour une therapie du cancer
EP4316599A3 (fr) Therapie antivirale
WO2004073599A3 (fr) Inhibiteurs du virus de l'hepatite c, compositions et traitements utilisant ces inhibiteurs
WO2008118849A3 (fr) Inhibiteurs de la protéase du vih-1
WO2011130557A3 (fr) Phosphonates présentant une toxicité réduite pour le traitement d'infections virales
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
WO2004106491A3 (fr) Therapies du vih-1 basees sur l'engiogenine
JP2008535798A5 (fr)
DK1303265T3 (da) Anvendelse af COX-2-inhibitorer, som immunostimulerende midler ved behandling af HIV eller AIDS
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
WO2008060695A3 (fr) Inhibition antivirale de la caséine kinase ii
WO2009069132A3 (fr) Nouveaux inhibiteurs de transcriptase inverse
WO2002026728A3 (fr) Procedes antiviraux et composes
WO2002026249A3 (fr) Nouveaux procedes destines a inhiber la replication du vih
EP2385145A3 (fr) Compositions et procédés permettant de déterminer la résistance des inhibiteurs à la saisie de virus à l'aide d'analyses de virus recombinants
WO2006116185A3 (fr) Procedes destines au traitement de myelomes multiples
BRPI0513321A (pt) vìrus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase